Session IX: Colon and Rectal Cancer: Early Disease

O-12: Phase II Study of Preoperative (Preop) Chemoradiotherapy (CTTRT) Plus Avelumab (AVE) In Patients (PTS) With Locally Advanced Rectal Cancer (LARC): The AVANA Study

Lisa Salvatore

The study authors conclude that the combination of preop chemotherapy plus avelumab showed promising activity and a feasible safety profile. According to their statistical considerations, the experimental regimen will be considered for further studies. Updated results are presented during the Congress.


SO-30: Efficacy and Safety of Neoadjuvant Short-Course Radiation Followed by mFOLFOX-6 plus Avelumab for Locally-Advanced Rectal Adenocarcinoma: Averectal Study

Ali I. Shamseddine

The study authors conclude that based on their analysis, the primary endpoint was successfully met with significant improvement in pathologic complete response (37.5%, p1⁄40.025) and major pathologic response rate rates in the setting of an acceptable safety profile. They note that 3-year disease-free survival and overall survival will be reported later in the final study manuscript.